On November 2, 2011, Finnegan client Cephalon filed suit against Breckenridge Pharmaceutical Inc. and Natco Ltd. for infringing a patent for Nuvigil®. The suit is in response to an abbreviated new drug application (ANDA) and a filed Paragraph IV certification claiming that Cephalon's patent either was invalid or would not be infringed by their generic product. Cephalon asked the court to block the defendants from selling their generic drug before its patent expires.
Justin A. Hendrix
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Charles T. Collins-Chase
District Court Rules in Favor of Finnegan Client Cephalon to Uphold Patent for Nuvigil®
March 30, 2013
James R. Barney
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.